Cross Reference to Related Applications This application claims priority from a Unites States Provisional Application No.

61/171,577 filed on 22 April 2009 by Palmer et al. The entire contents of that application are incorporated by reference herein.

Technical Field The present invention relates generally to medical devices and methods. More specifically, the present invention relates to devices and methods for extracorporeal circulation, analysis, filtering and conditioning of cerebrospinal fluid (CSF).

Background Art Cerebrospinal fluid (CSF) is a clear, watery fluid that surrounds the brain and spinal cord. It is produced in the human central nervous system (CNS) at a rate of about 0.3 ml/min in healthy adults. The total volume found in the ventricles and subarachnoid space is about 150ml at any moment. Thus the total volume is naturally replaced approximately 3 times a day. In normally functioning anatomy, the fluid naturally follows a circuit from production in the lateral ventricles, circulation over the surface of the brain and spinal cord and eventual drainage through the arachnoid granulations at the venous sinuses and lymphatic vessels. It is understood that due to the exposure of the fluid to the brain that the composition of the fluid can have a direct impact on the health of the brain with beneficial components in the fluid promoting brain health and pathogenic components having a deleterious effect on the brain. In fact pathology of a variety of compounds found within the CSF is increasingly understood, and it is believed that the elimination or treatment of these pathogens will lead to the prevention or amelioration of diseases such as Alzheimers, Parkinsons, Amyotrophic Lateral Sclerosis, Multiple Sclerosis and Guillain Barre Syndrome as well as others. The detection and removal, or at least reduction in concentration, of these compounds has been shown to have therapeutic effect. Likewise, the introduction of medicament into this fluid has also been shown to produce beneficial results. Given the relatively low rate of production of this low viscosity cerebrospinal fluid in the CNS and the presence of a natural production and re-adsorption process already ongoing there, the opportunity exists to create an extracorporeal circulation loop to treat the fluid in a space outside the sensitive environment of the CSF space. Accomplishing this direct conditioning of the CSF though, is made difficult by the very low volume of the space in the body that the fluid occupies and the sensitivity of the nerves and organs that are exposed to pressure and composition changes. Even slight fluctuations in intracranial pressure caused by incorrect removal or reintroduction rates of the fluid can cause pain or injury to the patient ranging from headache at the mild end to death. The problem is compounded by the small diameter and long length of the extracorporeal circulation which causes "head loss" during flow, with pressures dynamically increasing in front of restrictions, and decreasing behind restrictions in the flow loop. Anticipating these artificial pressure artifacts and extrapolating the native pressures in the patient can be difficult. In addition, the pressure in the extracorporeal circulation loop can change for a variety of other reasons such as restrictions (clogs, kinks, crushed tubing, closed valves, filter loading, etc), or changes in the patient's condition. (CSF leak, CSF overproduction, brain swelling, patient motion, etc). In light of this, measuring some pressures, such as patient ICP, is best preformed while the pump is stopped, while other pressures, such as transmembrane pressure at the CSF conditioning filter, are best performed while the pump is running. Information relevant to attempts to create such a treatment system can be found in US Patent Nos. 4,686,085; 4,904,237; 5,980,480; 6,575,928; 6,875,192; 7,309,330; 7,025,742; 7,189,221 and US Published Application Nos. 2003/006530; 2005/0038371; 20080033400; 2005/0010159. However, each one of these references suffers from one or more of the following shortcomings: they rely on passive drainage of the CSF to the extracorporeal circulation loop which limits the drainage to the natural generation rate of the fluid in the CNS thereby limiting the amount of fluid that can be treated in a reasonable treatment session; they provide imprecise measurement of pressure in the circulation loop which exposes the patient to risk of excessive or insufficient CSF pressure in subarachnoid space with all the attendant risks already mentioned for that condition; they measure the pressure in the circulation loop at only one location so that they are not assured that the pressure at the point of drainage and reintroduction are equivalent thereby potentially creating undesirable intracranial pressure fluctuations in the subarachnoid space; the pressure monitoring alarm limits applied by the referenced systems do not take into account the shape of the pressure waveforms that exists in CSF pumping system so they must be set outside optimal limit levels to avoid false alarms caused by natural spikes and troughs in pressure waveforms thereby exposing the patient to unsafe pressure fluctuations or sub-optimal flow rates; the pressure sensing performed by the referenced devices is not synchronized with the pumping states of the circulation pumps so they cannot distinguish between the native pressure attributed to the CNS and that caused by the pumps; they do not provide a mechanism for creating turbulence in the CSF that is reintroduced in the subarachnoid space to so there is not sufficient mixing of the conditioned CSF in that space limiting the 75 effectiveness of the treatment;, they replace the patient's drained CSF with synthetic CSF rather than the patient's own reconditioned CSF which may present compatibility issues and may not actually remove the toxins from the CSF but simply dilute it with non toxin containing artificial CSF; the dispensing of medicament into the CSF is not tied to the results of the compositional analysis of the fluid and the identification of pathogens in

80 the fluid so that dosages are not optimized according to the presence and concentration of pathogens.

Therefore what is needed is programmable cerebrospinal fluid conditioning system that does not rely on passive drainage, nor suffer from an imprecise pressure

85 sensing and control system which does not sense pressure at drainage and reintroduction points, cannot distinguish between the native pressure of the CSF system and the pressure induced by the pumping system and cannot apply adaptive alarms to the pressure-wave forms thereby avoiding false alarm conditions. Furthermore the device must not suffer from the inability to synchronize the dispensing of medicament

90 with the results of the compositional analysis.

Disclosure of Invention

The present disclosure advantageously addresses one or more of the aforementioned deficiencies in the field of CSF conditioning by providing a portable and 95 programmable CSF conditioning system that provides precise pressure monitoring and pumping control of the CSF through an extracorporeal fluid circuit as well as compositional analysis of pathogenic components of the fluid and dosing of medicament into the CSF in response to that analysis. It also provides turbulent reintroduction of the conditioned fluid into the subarachnoid space so that the conditioned fluid is more

100 thoroughly dispersed in the desired area.

The device is a closed loop extracorporeal fluid circuit for draining, pumping, controlling, analyzing and conditioning the flow of CSF for the purpose of treating brain injuries and disease. The system, designed to be worn by the patient in an in-patient or outpatient setting without connection to mobility impeding apparatus, actively pumps fluid

105 from the subarachnoid space of a patient through the lumens of a specialized catheter which is positioned in this space. It then circulates the fluid through an attached circuit at desired pressures and rates so that the fluid can be analyzed by a variety of sensors, treated by filters and medicament dispensers and reintroduced through another lumen of the same or separate catheter. In some embodiments the point of attachment of the

110 catheter is in the lumbar thoracic or cervical CSF space. In yet another embodiment, the drain and return points may be positioned in different CSF spaces, for example the drain may by attached in the lumbar thoracic CSF space while the return is in the subarachnoid CSF space.

One embodiment of the device comprises a specialized, multi-lumen catheter for

115 accessing the subarachnoid space for purposes of draining and re-introducing the CSF from that space through the different lumens of the catheter. The lumens of the catheter are connected to a fluid circuit which guides the flow of the CSF outside the body. Integrated into the circuit are other components such as pressure sensors for measuring the pressure at various locations along the circuit, devices for compositional analysis of

120 the fluid, filter banks for removing targeted compounds from the CSF, medicament dispensers for dosing medicine into the fluid and pumps for controlling the flow of the CSF and for creating pressure waveforms in the flow. The sensors, filters, pumps and dispensers are also electrically connected to a controller for synchronizing the operation of the various units in a manner that optimizes the CSF conditioning process with the first

125 order of optimization being that of collecting accurate pressure readings and the second being the minimization of undesirable pressure fluctuations in the system due to sub- optimal pumping control and the third being the synchronization of medicament dispensing with the results of the compositional analysis. The controller can toggle the pump between on and off duty cycle and can further synchronize the collection of

130 pressure measurements with these pump states so that the system can record measurements in both the pump stopped, and pump running state conditions, each of which provide a specific and unique piece of data about the system. The pressure readings collected during the various pump states can then be analyzed by the microprocessor in order to determine true intracranial and transmembrane pressures.

135 In another embodiment the system may additionally measure the time constants of the transients in the pressure wave-forms following the pump starting or stopping (how long the system takes to reach steady state and the shape of the pressure build or decay curves). These time constants may provide diagnostic information for system configuration or performance. At the beginning of therapy, a time constant outside of

140 normal parameters may indicate an incorrectly configured flow loop. Over the course of therapy, changes in the time constants may indicate impending need for maintenance of the conditioning element or some component of the fluid circuit.

In another embodiments it is anticipated that there will be a need for pressure alarms such as: static ICP too high, static ICP too low, running drain or return pressures

145 outside of limits, transmembrane pressure at the conditioning element too high, or pulsatility too low (note that measurement of pulsatility from patient breathing or cardiac cycle is normal, and the absence of that pulsatility may be interpreted as a possibly occluded flow path or other problem). Normally the alarms relevant to static pressures should only be triggered during static measurement, and the alarms relevant to dynamic

150 pressures should only be triggered during pump running steady state conditions. If the system measures and records the characteristics of the pressure transients, these alarm set-points can be adaptable to vary with the system's duty cycle, not only in the "steady - on" condition, or "steady-off ¹ condition, but also potentially during the transient conditions.

155 In yet another embodiment the measured pressures approaching an alarm condition may cause the system to adapt its operation, such as slowing down the flow if the transmembrane or patient return flow pressure is too high.

In another embodiment the system measurements may include detection of the presence and concentration of deleterious or beneficial elements in the CSF. For

160 example if the therapeutic target is the prevention of vasospasm post hemorrhage by blood removal; the system may include one or more optical measurement flow cells which measure red blood cell concentration in the CSF, oxygen saturation level of the red blood cells, the concentration of free hemoglobin, etc. These data may be tracked and integrated with flow data to track total blood removed, changes in the condition of

165 the blood, and potentially predict either the completion of therapy by removal of all blood, or the onset of vasospasm due to the breakdown of remaining blood in the CSF.

In other embodiments the integrated measurement of total blood filtered from the CSF, trends in historical pressure measurements, or residence time of the cells on the filter membrane allow for prediction of required service interval for the CSF conditioning

170 element, either by element replacement, or purging.

In another embodiments the system may incorporate the capability to deliver therapeutic agents to the CSF if certain alarm conditions are approached or met, such as delivering vasodilators if the conditions believed to trigger vasospasm are observed.

In some embodiments, the system can include a capability for intentional use of

175 increasing and decreasing pressure waveforms within an acceptable range and over a defined time span. Natural bulk and oscillatory flow of CSF between the spinal and cerebral areas is slow, so actively increasing the exchange and mixing of fluid between the intracranial and spinal region is anticipated to have the advantage of enhancing the effectiveness and efficiency of the CSF conditioning process, resulting in potentially

180 improved patient outcomes. These pressure cycles promote flow between intracranial and intraspinal space due to the relative inelasticity of volume in the spinal space, and elasticity (compliance) of volume in the intracranial space. As a net volume of fluid is pumped in through the lumbar catheter, there is a bulk flow from the intraspinal space into the intracranial space as the brain and blood vessels contract due to the increased

185 pressure. When this is reversed with a new fluid drainage, a bulk flow from intracranial to intraspinal spaces occurs. In this oscillatory flow, the transport of blood in the CSF or other deleterious agents out of the intracranial space may be enhanced, carrying them into an area where the dual lumen catheter circulation and filtering can be more effective. This effect may be achieved by incorporating an extracorporeal reservoir of fluid

190 (collected native CSF ₁ or a bio-compatible CSF replacement, or other therapeutic fluid), where net increase or decrease of the fluid in the body can be pumped from or to this reservoir causing the pressure cycles.

In still another embodiment, the control algorithms which control the shape and timing of the pressure waveforms may vary so as to have a maximizing effect of the fluid

195 movement within the patient, especially in regard to the exchange of fluid between the cerebral and spinal regions. For example, a gradually increasing and then comparatively more rapidly decreasing pressure may have a beneficial fluid exchange effect. Other waveforms may also provide a therapeutic benefit as determined by further experimentation. In addition, the timing of the pressure cycle can be so designed to take

200 advantage of the natural pressure cycles and compliance of tissue within this space, for example by synchronizing with cardiac or respiratory cycles.

In an alternate embodiment, the CSF is not circulated but is instead drained internally or externally to the body while at the same time artificial CSF is introduced through a separate line. Pressure sensors are attached to the infusion line while

205 pressure and optical sensors are attached to the drain line and the signals collected by those devices are transmitted to the controller for analysis. Since the patient's CSF is not being reintroduced the need for filtering is obviated. The infusion line may also be configured for the introduction of medicament, as in the preferred embodiment, although here it is introduced on a separate infusion line which also has a pressure wave unit

210 attached to it as in the preferred embodiment. The advantage of this embodiment, as stated earlier, is that the filter bank is eliminated but because this configuration requires an artificial source of CSF the arrangement is not as self contained and would likely reduce the patients' mobility.

In some embodiments the measuring elements (pressure, compositional, etc) are

215 collocated with the control and pumping unit while in others they may be remotely located from the control and pumping unit. For example attached to the extracorporeal fluid path, or embedded in the intraspinal catheter.

A novel and non obvious feature of the device and associated method is the 220 synchronization of the pressure measurement function with the pumping control and pressure waveform generation functions so that more precise pressure measurements can be made. Another novel and non obvious feature of the device is the application of sophisticated process control apparatus to the system which provides for the 225 synchronization of the sensing, analysis and diagnostic functions with the pump duty cycle of the system in order to customize the treatment and therapeutic activities based on the feedback from transducers, compositional analysis sensors, and filters and the analysis of that feedback by the controller.

Another novel feature is the generation of pressure waveforms in the circulated 230 fluid in order to create turbulence at the fluid reintroduction point so there is more complete mixing of the fluid in the subarachnoid space, or in the bulk flow between the intracranial and intraspinal spaces if the drain and return points are positioned in a manner to promote flow through those regions.

Another novel feature is the feedback of the results of the compositional analysis 235 to the controller so that dosing of medicament is influenced by the composition of the fluid.

The device may afford the user one or more of the following advantages: a. enhanced pressure monitoring in both the drain and reintroduction flows by 240 applying an on/off duty cycle to the re-circulation and waveform pumps and then synchronizing the pressure sensing with that cycle so that measurements are recorded under both the static and dynamic conditions. This provides for enhanced precision of measurement of the patient's intracranial pressure (ICP), which is best measured under static conditions, and the transmembrane pressure of the filters, which is best measured 245 under dynamic conditions. Precise measurements of these two pressures are provided as feedback to the controller which responds with modulations to the pumping waveform and filter maintenance schedule which would not be available without this feature. b. integrated feedback of therapy effectiveness by examining trends in pathogen concentrations detected by sensors and using that information to analyze filter

250 effectiveness in the device and pathogen production rates in the patient; this information could then be used to modify the treatment regimen in real time; c. enhanced control of pressure waveforms to promote mixing of the medicament in the circulation circuit and in the CSF space. Because the bulk and oscillatory flow of CSF between the spinal and cerebral areas is slow, actively increasing the exchange

255 and mixing of fluid between the intracranial and spinal regions is anticipated to have the advantage of enhancing the effectiveness of the CSF filtering and infusion process. Since the volume in the spinal space is quite inelastic while the volume of the intracranial space is somewhat more compliant, oscillations caused by induced pressure waveforms from the device should improve the transport of deleterious agents out of the intracranial 260 space and into areas where they can be accessed by the catheter ports; d. the ability to synchronize the generation of pressure waveforms in order to take advantage of native pressure cycles and compliance of tissue that may exist with cardiac or respiratory cycles; e. the ability to measure the time constants of the transients following pump start 265 and stop and, based on the change to the shape of the transient curve over time, use this information as an indicator of the need for filter change out, maintenance functions or configuration adjustments; f. adaptive pressure waveform generation and alarm control which reduces the pumping pressures as measured pressures approach alarm conditions while also

270 allowing for alarm limits to the follow the shape of pressure waveforms so that tighter pumping control can be provided without the risk of false alarms; g. historical usage and trend monitoring so that consumables that are approaching end of life can be exchanged before alarm conditions are exceeded and so that treatment algorithms can be optimized based on extrapolation of past trends in

275 filtration efficiency and medicament delivery and distribution.

It is therefore the purpose of this invention to treat diseases of the brain and central nervous system by draining, conditioning and reintroducing CSF via a portable, extracorporeal fluid circuit which provides automated compositional analysis, filtering and 280 dispensing of medicament under precise pressure control and pumping conditions.

The present invention will now be described more fully with reference to the accompanying drawings, which are intended to be read in conjunction with both this summary, the detailed description, and any preferred or particular embodiments 285 specifically discussed or otherwise disclosed. This invention may, however, be embodied in many different forms and should not be construed as limited to the embodiments set forth herein; rather, these embodiments are provided by way of illustration only so that this disclosure will be thorough, and fully convey the full scope of the invention to those skilled in the art. 290

Brief Description of Drawings

FIG. 1 is a block diagram of the system and subsystems. FIG. 2 is a schematic of the system showing relative positioning of the components of the system in the fluid circuit. 295 FIG. 3 is an illustration of the system connected to a patient. FIG. 4A is a diagram of the pressure waveforms created by the pump duty cycle and the associated static alarm limits.

FIG. 4B is a diagram of the pressure waveforms created by the pump duty cycles and the associated adaptive alarm limits. 300

Best Mode for Carrying out the Invention

To provide context for the invention, it may be useful to understand that Cerebrospinal fluid (CSF) is produced in the human central nervous system (CNS),

305 primarily in the choroid plexus in the ventricles of the brain. The normally clear, watery fluid maintains a gradient between it and the interstitial fluid of the nervous system. Thus many neurotransmitters, peptides and other neuroactive substances can be found within the CSF. Although the functional role of many of these peptides is currently under research, there are two functions of CSF that are presently understood: 1) by

310 surrounding and bouying the brain and spinal cord it provide a protective function upon impact to the skull or spinal column; 2) and it contributes to the maintenance of a constant composition of the neuronal environment.

In healthy adults, CSF is produced at a rate of about 0.3 ml/min and the total volume found in the ventricles and subarachnoid space is about 150ml at any moment.

315 Thus the total volume is naturally replaced approximately 3 times a day. In normally functioning anatomy, the fluid naturally follows a circuit from production in the lateral ventricles, circulation over the surface of the brain and spinal cord and eventual drainage through the arachnoid granulation at the venous sinuses and lymphatic vessels. The concentration of various neuroactive substances in the CSF is of great

320 interest, because it represents a direct view of the extracellular fluid in the immediate vicinity of the neurons of the brain and spinal cord. In the same manner that beneficial components of this fluid likely serve to maintain the health and function of the brain, the presence of pathogens and other unwanted compounds in this fluid are thought to have a direct and deleterious effect on the CNS. The pathology of a variety of endogenous

325 and exogenous pathogens found within the CSF is increasingly understood and it is believed that the elimination or treatment of these pathogens will lead to the prevention or amelioration of diseases such as Alzheimers, Parkinsons, Amyotrophic Lateral Sclerosis, Multiple Sclerosis and Guillain Barre Syndron as well as others. In addition to the compounds and the associated disorders already mentioned, physical injury to the

330 brain can also introduce elements into the CSF which impede the healing of the injury.

Whether the source of unwanted compounds in the CSF is disease or injury, the detection and removal, or at least reduction in concentration, of these compounds has been shown to have therapeutic effect. Furthermore, the introduction of medicament into this fluid has also been shown to produce beneficial results. This treatment can prevent

335 or reduce the severity of many brain diseases and injuries that result from the exposure of the brain to these pathogens, proteins, and other unwanted compounds.

This description of anatomy and physiology is provided in order to facilitate an understanding of the invention. Persons of skill in the art will also appreciate that the scope and nature of the invention is not limited by the anatomy discussion provided.

340

Detailed Description

The device 10 is a closed loop extracorporeal fluid circuit 30 for draining, pumping, controlling, analyzing and conditioning the cerebrospinal fluid (CSF) for the purpose of treating brain injuries and disease and is designed to be worn by the patient

345 16 in an in-patient or outpatient setting without connection to mobility impeding apparatus. The device 10 comprises a multi-lumen catheter 20 for accessing the CSF in the subarachoid space 14, fluid drain 21 and fluid return lines 22, a plurality of pressure sensors 41, 42, 42, compositional analysis sensors 45, a filter bank 50, a circulation pump 65, a medicament dispenser 80, a pressure wave generating system with

350 reservoir 70, and a controller 100.

Starting at the point where the CSF exits the patient's body 16 through the lumen 21 of a temporarily inserted, specialty catheter 20, the catheter connects to a fluid drain line 31. The drain line 31 comprises standard medical attachment hardware, medical

355 grade fluid tubing and a pressure transducer 41. The tubing is made of material which can be laterally flexed to accommodate positioning requirements but which limits volumetric expansion or contraction under pumping conditions. Suitable materials used in simple monolithic or composite structures include typical cardiovascular and neurovascular catheter materials such as silicone, polyvinychloride, urethane and other

360 common medical grade polymers. Since precise pressure monitoring is crucial to the optimal function of the system, the pressure transducer 41 is positioned in the line 31 as close to the union with the catheter 20 as practical in order to avoid distortion of the signal by line loss or undesired perturbations in the system. The transducer 41 has an inlet and outlet port for connection to the fluid circuit and will be connected through the

365 power 127 and data grid 128 to the controller 100. The transducer 41 may be commanded by the controller 100 to measure and transmit signals in a continuous mode or may be commanded to measure according to some schedule. The outlet port of the transducer is connected to additional tubing needed to move the fluid further along the circuit 30. 370 The device 10 further comprises compositional analysis sensors 45 which are designed to detect the presence and concentration of various constituent elements of the CSF including, but not limited to, the concentration of red blood cells, the oxygenated state of the blood, the concentration of free hemoglobin from lysed cells, and bilirubin. The sensors 45 may comprise LED emitters capable of emitting discrete wavelengths of

375 light at desired wavelengths and detectors which sense either the emitted light after it has passed through or been reflected by particles in the fluid, or light induced by flouresence from substances in the fluid . The presence of certain elements in the fluid cause intensity shifts at specified wavelengths with the relative intensities create by each constituent fluid component of interest being reversed for the emitted wavelengths. This

380 two point sensing algorithm aids in the precision of measurement. Sensing accomplished by the collector is transmitted to the controller 100 where it is converted to digital form for analysis, data storage and treatment scheme response. The compositional analysis sensors 45 can be arrayed sequentially or in parallel and may be situated as a stand-alone unit somewhere along the fluid circuit 30 or as an integrated

385 unit of the console 60. The only positional requirement being that it must be located along the fluid circuit 30 so that the sensors 45 can view the fluid as it passes, and preferentially while the fluid is in motion to avoid settling of cells or particulate in stagnant fluid. Once the CSF has flowed passed the sensors 45 it will continue to flow through the extracorporeal circuit 30.

390 A filter bank 50 is positioned in the circuit 30 in order to removed target pathogens from the CSF which may contribute to diseases of the brain. The filter bank 50 comprises a plurality of cartridges 55 containing disposable membranes, a purge mechanism and a filter transmembrane pressure transducer 42. The cartridges 55 are hollow housings capable of removal or reinsertion. They are arrayed in parallel or series

395 within the filter bank 50 to facilitate switching between filters and sequestering the filtrate out of the flow loop after some period of time. The filter membranes are disposable hollow fiber membranes, or convoluted sheets with high surface area to volume ratios. The membranes are selected by pore size and capacity depending on the type of compound to be removed from the fluid. Each parallel filter cartridge 55 is isolated from

400 an upstream and downstream manifold by electrically actuated isolation valves 51 so that cartridges 55 in one path can be isolated and replaced while allowing the fluid flow to continue through parallel paths. The filter cartridges 55 may be configured with the same filter membranes, in which case they are operated in parallel, or different filters in which case the filters not desired for current use are isolated by upstream and 05 downstream valves 51. The filter bank 50 further comprises a purge unit which is connected to each filter cartridge in order to back-flow or tangentially flow a fluid through the filter in the event the filter is clogged or needs to be cleaned. The filter bank 50 further comprises a pressure transducer 42 in parallel with the filter cartridges 55 to measure transmembrane pressure and transmit that information via attached data grid

410 128 to the controller 100 where the information is stored and analyzed for the purpose of triggering maintenance prompts and alarms.

The device 10 further comprises a motorized circulation pump 65 connected to the fluid circuit 30 downstream from the filter bank 50 for the purpose of pumping the CSF from the subarachnoid space 14 through the extracorporeal circuit 30. The pump

415 65 comprises a housing, inlet's and outlets for connection to the circuit 30 and a mechanical pumping mechanism. The pumping mechanism can be any type of commonly used mechanical pump such as a peristaltic roller, piston, bellows, pneumatic, screw mechanism or any other suitable means for creating vacuum or pressure in the range of +/- 200 mmHg. The housing surrounding the moving pumping mechanism is in

420 place in order to shield collocated components from entanglement in the moving components of the pumping mechanism. The pump 65 is connected to a power supply via the power grid 127 and is connected to controller via the data grid 128 so that it may received signals for the purpose of controlling the pump's state. It is desirable that the pump 65 be located downstream from the filter bank 50 so that any blood cells in the

425 CSF are removed prior to pumping, to avoid hemolysis. Otherwise, vasospasm from blood degradation by-products may be accelerated.

The system further comprises a medicament dispenser 80 attached to the fluid circuit 30. The dispenser 80 comprises an electrically actuated isolation valve 82 connected to the fluid circuit 30, a reservoir 85 for holding medicament, and a pressure

430 source 87, 88 for infusing the medicament into the fluid circuit 30. The isolation valve 82 is an electrically powered valve and is connected to the power supply and the central processor and controller by power 127 and data grid 128. The valve 82 opens in response to signals sent from the controller 100 which controls the dispensing of medicament into the fluid stream while the pressure created by the pump 87 or pressure

435 cartridge 88 inject the medicament into the CSF circuit. Alternately, it may be a passive pressure valve that only opens upon injection of the therapeutic agent under pressure. The medicament reservoir 75 comprises a chamber to hold fluid medicament with a port opening to the isolation valve 82 and a second port which exposes the chamber to the pressure source 87, 88. The pressure source 87, 88 can be any pumping mechanism or

440 a replaceable pressure cartridge and exerts pressure on the fluid in the medicament reservoir thereby infusing it into the fluid circuit when the isolation valve 82 is opened. The medicament dispenser 80 may be positioned anywhere downstream of the filter bank 50 but preferably downstream of the re-circulation pump 65. A pressure waveform generating unit 70 may also attached to the fluid circuit and

445 comprises a section of tubing 78, a motor driven pump 72 and a fluid reservoir 75. The purpose of the unit 70 is to create pressure waveforms in the circulating CSF in order promote mixing of the CSF between the intracranial and intraspinal spaces, thereby improving the distribution of the conditioned CSF in those spaces. The tubing 78 connects to the fluid circuit 30 and runs through the mixing pump 72 and into a reservoir

450 75. The pump 72 may be electrically powered and can be any of the kinds previously described for the circulation pump 65. It can be connected to the power supply 125 and controller 100 via the power 127 and data grid 128 respectively. The reservoir 75 is in line with the pump 72 and may be positioned upstream or downstream of the pump in the wave generating unit 70. When activated, the pump 72 draws in CSF from the fluid

455 circuit 30 to the reservoir 75 and then expels it back into the circuit in response to commands sent by the controller 100. The pressure-wave generating unit 70 may be located anywhere in the circuit 30 downstream of the circulation pump 65.

The device 10 further comprises a return line 35 to transport the conditioned fluid from the pressure waveform generator 70 to the return lumen 25 of the catheter 20. The

460 return line 35 may contain a pressure transducer 43 to sense the actual pressure created by the combination of native pressure in the CSF from the patient, as well as the pressure created by the circulation pump 65 and the pressure waveform generator 70. The transducer may be situated in the fluid circuit 30 as close as possible to the point where the CSF is re-introduced into the body, preferably just upstream of the union

465 between the fluid return line 35 and the lumen 25 of the catheter 20 used to re-introduce the fluid into the patient's body 16. The transducer is connected by the data grid 128 to the controller 100 and transmits signals to that unit which describe the actual waveform present in the circuit.

The device further comprises a controller 100 which controls the functionality of

470 the device by: receiving user inputs from the user interface 115, receiving analog and digital signals from the electromechanical systems 12, analyzing the received signals, storing and retrieving data from the memory, applying algorithms to the data and signals, and sending analog and digital commands to various components in order to accomplish the functions of the device. The controller consists of a central processing unit (CPU)

475 103, an analog to digital converter 104, a programmable memory 105 and algorithm unit 108, and a command output unit 106. The programmable memory 105 comprises an EPROM or other programmable memory for programming with various software algorithms and code. It communicates with the CPU 103 of the controller 100 and applies the software algorithms 108 to direct the controller 100 functions. 480 The controller 100 is connected to the external input/output 112 which contains the user interface 115 and manufacturer's interface 118. The user interface 115 displays information including but not limited to, instantaneous data from pressure transducers 41, 42, 43 and compositional analysis sensors 45, processed data such as flow rates and pressure waveforms, historical data such as filter life and volume of medicament

485 dispensed. The user interface 115 also accepts inputs from the user including but not limited to, on/off commands, selection of pumping algorithms and waveforms, selection of medicament dispensing routines, and alarm conditions. The manufacturer's interface 118 comprises an electrical interface compatible with standardized electrical cabling such as USB, Firewire, and RS232 ports to facilitate the loading of software and

490 algorithms.

The device 10 also comprises a power controller 125 and power supply 120. The power supply 120 may be any AC or DC source but preferably a DC rechargeable supply. It provides power to the controller 100 and the electromechanical systems 12. The device 10 also comprises an alarm unit 90 that can be triggered when limits

495 set in the pumping and pressure sensing algorithms are exceeded. The alarms comprise audible alarm tones and visible message displays on the user interface 115. In addition alarms can be configured to trigger power relays in order to halt operations of the unit.

500 In a preferred embodiment the power supply 120, and controller 100 as well as the compositional analysis sensors 45, filter bank 50, circulation pump 65, medicament dispenser 80 and pressure waveform generator 70 are all consolidated in a single, integrated console 60 that is wearable by the patient on a belt or other load-bearing device. In that case the only components not integrated into the console would be the

505 fluid drain 21 and fluid return lines 25 as well as the pressure transducers 41 , 42 positioned near the terminus of each of those sections of line. The advantage of this embodiment is the mobility it provides to the patient, a reduction of risk associated with tangling of tubing and pulling out of catheters, as well as obviating the need to drain CSF into another body cavity or to provide artificial CSF for mixing with the medicament for

510 infusion.

In an alternate embodiment, the CSF is not re-circulated but is instead drained internally or externally to the body while at the same time artificial CSF is introduced through a separate infusion line. Pressure transducers 43 are attached to the infusion line while another pressure transducer 41 and compositional analysis sensors 45 are

515 attached to the drain line 31 and the signals collected by those devices are transmitted to the controller 100 for analysis. Since the patient's CSF is not being reintroduced the need for filtering is obviated. In this configuration the medicament is introduce on the infusion line which also has a pressure waveform generator 70 attached to it. The advantage of this embodiment, as stated earlier, is that the filter bank 50 is eliminated

520 but because this configuration requires an artificial source of CSF the arrangement is not as self contained and would likely reduce the patients' mobility.

While exemplary embodiments of the present disclosure have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions will

525 occur to those skilled in the art without departing from the disclosure. It should further be understood that various alternatives to the embodiments of the disclosure described herein may be employed in practicing the invention.

Industrial Applicability

530 Whatever embodiment is chosen, the device 10 is used by attaching the CSF drain 21 and return 25 lines and their associated transducers 41, 43 to a specialty catheter 20 which has been inserted into the patient's spine and subarachnoid space in order to access the CSF. The user inputs the parameters of a desired treatment regimen including but not limited to treatment time, pumping volume, dispensing volume

535 and pathogen concentration by means of the user interface. The CSF is then pumped through the fluid circuit 30 under precise pressure monitoring and control. The compositional analysis sensors 45 identify types and concentrations of pathogens or unwanted compounds in the blood and provide this information to the controller 100 which monitors the trends in concentration levels and responds by applying custom

540 medicament treatment routines that are indicated by the analysis of the patient's CSF. In stream filters 50 remove target pathogens from the CSF with the resulting decreasing concentration of the pathogens being confirmed by the optical sensors. The medicaments dispensed by the dispenser 80 may provide therapy to the brain and can be dispensed under precisely monitored conditions whereby instantaneous and historical

545 data may be synthesized by the controller 100 so that the therapy regime is continuously updated based on feedback from the compositional analysis sensors 45 which indicate the changing concentrations of pathogens as a result of the filtering and treatment of the CSF. The pressure waveform generator 70 further tailors the therapy by not only ensuring the medicament is mixed with the in-line CSF but also by promoting turbulence

550 or bulk flow inside the subarachnoid space to ensure enhanced distribution of the medicament and treated fluid. The controller 100 analyzes the inputs from the pressure 41, 42, 43 and compositional analysis sensors 45 as well as historical data stored in the memory 105 and modifies operating algorithms and treatment regimens by changing pump duty cycles, sampling schemes and medicament dosages to customize the 555 treatment. In addition the controller 100 can apply adaptive alarms and usage alarms to ensure safety and maintenance limits are adhered to.

While exemplary methods of use of the present disclosure have been shown and described herein, it will be obvious to those skilled in the art that such methods are 560 provided by way of example only and that other methods of employment are also contemplated by this disclosure.

565

570

575

580

585

590